Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-19.7	-22.76	-21.4	-18.66	-12.42	-8.03
Depreciation & Amortization	0.03	0.03	0.03	0.04	0.02	0.02
Share-Based Compensation	1.28	1.47	1.51	1.16	0.43	0.47
Other Operating Activities	8.66	4.94	-1.17	-1.28	0.06	-2.1
Operating Cash Flow	-9.73	-16.11	-20.83	-18.54	-7.93	-9.45
Capital Expenditures	0	-0.01	-0.01	-0.03	-0.1	0.03
Investing Cash Flow	0	-0.01	-0.01	-0.03	-0.1	0.03
Share Issuance / Repurchase	1.05	1.05	3.2	21.94	29.71	4.05
Other Financing Activities	-0.23	-0.2	-0.2	-0.2	-0.2	-0.2
Financing Cash Flow	0.82	0.85	3	21.74	29.5	3.85
Exchange Rate Effect	0.28	0.3	-0.38	-0.02	0.05	-0.05
Net Cash Flow	-8.64	-14.97	-18.21	3.15	21.52	-5.62
Free Cash Flow	-9.73	-16.12	-20.83	-18.57	-8.03	-9.42
Free Cash Flow Margin	-2167.93%	-3837.62%	-	-	-	-
Free Cash Flow Per Share	-7.38	-19.12	-27.77	-31.20	-33.15	-173.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).